New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Trial ID or NCT#
Status
RECRUITING
Purpose
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Official Title
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Eligibility Criteria
- - Pathology-confirmed diagnosis of metastatic RCC - At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging - Planned to be treated with VEGFR2 tyrosine kinase inhibitor plus immune checkpoint inhibitor - Written informed consent
- Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study.
Investigator(s)
Contact us to find out if this trial is right for you.
CONTACT
Christian Hoerner, PhD
(650) 721-3206
View on ClinicalTrials.gov
About this Clinical Trial
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Your Message Will Go To
Christian Hoerner, PhD650-721-3206